About Dr. Shi Yingqiang
Dr. Shi Yingqiang (师英强) is a Professor, Doctoral Supervisor, and one of China's foremost surgical oncologists specializing in soft tissue tumors and sarcomas, based at the Department of Soft Tissue Surgery, Fudan University Shanghai Cancer Center (FUSCC). With extensive clinical and research expertise in the surgical management of soft tissue sarcomas, bone sarcomas, gastrointestinal stromal tumors (GISTs), retroperitoneal sarcomas, and other rare mesenchymal tumors, Dr. Shi is recognized as a national authority in sarcoma surgery at China's foremost dedicated cancer center — one of the highest-volume sarcoma programs in Asia.
Soft tissue sarcomas are a heterogeneous group of rare malignant tumors arising from mesenchymal tissues — including fat, muscle, nerve, blood vessels, and connective tissue — that collectively account for approximately 1% of adult malignancies but encompass more than 70 distinct histological subtypes with widely varying biological behavior, treatment sensitivity, and prognosis. The rarity and histological diversity of sarcomas mean that their optimal management — including precise histological and molecular subtyping, surgical planning for wide local excision with negative margins, and the selection of appropriate neoadjuvant and adjuvant systemic therapy and radiotherapy — requires a level of specialist expertise and institutional volume that is available at only a small number of dedicated sarcoma centers worldwide. Dr. Shi's clinical practice at FUSCC — supported by the center's comprehensive sarcoma multidisciplinary team integrating surgical oncology, medical oncology, radiation oncology, pathology, and radiology — provides international patients with access to the most advanced sarcoma management available in China.
Hospital Affiliation: Department of Soft Tissue Surgery, Fudan University Shanghai Cancer Center
Fudan University Shanghai Cancer Center (FUSCC) is China's foremost dedicated cancer center. Its Department of Soft Tissue Surgery is one of the highest-volume sarcoma surgery programs in China and Asia, managing hundreds of new sarcoma cases annually across all major histological subtypes and anatomical locations. The department's sarcoma multidisciplinary team — one of the most active in China — integrates surgical oncology, medical oncology (sarcoma-specific chemotherapy and targeted therapy), radiation oncology (IMRT, SBRT, intraoperative radiotherapy), pathology (sarcoma-specialized histopathology and molecular diagnostics), and radiology (MRI, CT, PET-CT) for comprehensive sarcoma management. The department participates actively in national and international clinical trials of novel systemic therapies for sarcoma, providing access to investigational agents for patients with advanced or refractory disease.
Clinical Specialties: What Dr. Shi Yingqiang Treats
- Extremity and trunk soft tissue sarcomas — wide local excision with negative margins for extremity and trunk soft tissue sarcomas; limb-salvage surgery for extremity sarcomas with neurovascular involvement; vascular resection and reconstruction for sarcomas encasing major vessels; nerve-sparing techniques for sarcomas adjacent to major peripheral nerves; plastic surgery coordination for soft tissue reconstruction after wide excision; coordination with radiation oncology for neoadjuvant and adjuvant radiotherapy; coordination with medical oncology for neoadjuvant and adjuvant chemotherapy for high-grade sarcomas
- Retroperitoneal sarcomas — extended resection of retroperitoneal sarcomas including en bloc resection of adjacent organs (kidney, colon, psoas muscle) for complete gross resection; management of retroperitoneal liposarcoma recurrence; coordination with radiation oncology for neoadjuvant IMRT for retroperitoneal sarcoma; multidisciplinary tumor board review for complex retroperitoneal sarcoma cases
- Gastrointestinal stromal tumors (GISTs) — surgical resection of primary GISTs including laparoscopic and open approaches; R0 resection planning based on tumor location, size, and relationship to adjacent structures; coordination with pathology for KIT/PDGFRA mutation genotyping; imatinib neoadjuvant therapy for large or anatomically challenging GISTs to reduce tumor size before surgery; adjuvant imatinib therapy based on risk stratification and mutation status; management of imatinib-resistant GISTs including sunitinib and regorafenib; avapritinib for PDGFRA D842V-mutant GISTs
- Bone sarcomas — limb-salvage surgery for osteosarcoma and Ewing sarcoma including endoprosthetic reconstruction and biological reconstruction; coordination with medical oncology for neoadjuvant and adjuvant chemotherapy (MAP protocol for osteosarcoma, VDC/IE for Ewing sarcoma); chondrosarcoma resection; giant cell tumor of bone management including denosumab neoadjuvant therapy and surgical resection
- Desmoid tumors — surgical resection for symptomatic or progressive desmoid tumors; active surveillance for stable asymptomatic desmoid tumors; sorafenib and pazopanib systemic therapy for unresectable or recurrent desmoid tumors; coordination with gastroenterology for FAP-associated desmoid tumors
- Rare sarcoma subtypes — surgical management of synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), epithelioid sarcoma, clear cell sarcoma, alveolar soft part sarcoma, and other rare sarcoma subtypes; molecular profiling for identification of actionable alterations and clinical trial eligibility; coordination with medical oncology for subtype-specific systemic therapy including trabectedin for liposarcoma and leiomyosarcoma, pazopanib for non-adipocytic sarcomas, and immunotherapy for selected subtypes
- Metastatic sarcoma management — pulmonary metastasectomy for resectable lung metastases from sarcoma; resection of oligometastatic disease at other sites; coordination with medical oncology for systemic therapy for unresectable metastatic sarcoma; coordination with radiation oncology for SBRT for oligometastatic sarcoma
- Expert second opinion on sarcoma diagnosis and management — review of pathology slides, molecular profiling results, imaging, and treatment records for patients with sarcoma seeking a second opinion on histological diagnosis, surgical planning, or systemic therapy selection; written English-language second opinion reports available through CMCS
Why International Patients Choose Dr. Shi Yingqiang and FUSCC
International patients seek sarcoma consultation with Dr. Shi Yingqiang and FUSCC for reasons that reflect the fundamental importance of institutional volume and specialist expertise in sarcoma management — a domain where outcomes are strongly correlated with the experience of the treating center.
For patients with extremity sarcomas who have been told that amputation is necessary, Dr. Shi's expertise in limb-salvage surgery — including vascular resection and reconstruction, nerve-sparing techniques, and plastic surgery coordination for soft tissue reconstruction — frequently identifies a limb-preserving surgical approach that achieves equivalent oncological outcomes to amputation while preserving function and quality of life. The combination of Dr. Shi's surgical expertise and FUSCC's multidisciplinary sarcoma team — including radiation oncology for neoadjuvant radiotherapy to facilitate limb salvage — provides a level of sarcoma management sophistication that is available at only a small number of centers in China.
For patients with GISTs, Dr. Shi's expertise in GIST surgery — combined with FUSCC's pathology department's capability for comprehensive KIT/PDGFRA mutation genotyping and Dr. Shi's close collaboration with the medical oncology team for imatinib neoadjuvant and adjuvant therapy — provides the integrated surgical and medical management that optimal GIST care requires. For patients with PDGFRA D842V-mutant GISTs — which are resistant to imatinib but sensitive to avapritinib — the precise mutation genotyping available at FUSCC is essential for identifying the correct treatment approach.
The cost of sarcoma surgery consultation and surgery at FUSCC is substantially below that of equivalent care at dedicated sarcoma centers in Western healthcare systems, and access to specialist consultation can typically be arranged within days through CMCS.
What to Expect at Your Consultation
Consultations with Dr. Shi Yingqiang at FUSCC arranged through CMCS begin with a comprehensive review of all prior records — including MRI and CT of the primary tumor, chest CT and PET-CT for staging, pathology reports and molecular profiling results (including KIT/PDGFRA mutation status for GISTs), prior surgical records, and prior systemic therapy and radiotherapy records. CMCS will arrange certified translation of all medical records and imaging reports in advance of the consultation. Dr. Shi will assess the tumor histology, stage, and resectability, evaluate surgical approach and limb-salvage options, outline the recommended multimodal treatment strategy with detailed rationale, and coordinate multidisciplinary tumor board review. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Shi's team and the patient's home oncologist or surgeon for continuity of care planning.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking sarcoma consultation with Dr. Shi Yingqiang at Fudan University Shanghai Cancer Center. Our services include priority consultation scheduling, certified medical record and pathology report translation, coordination of MRI, CT, and PET-CT imaging, on-site interpretation, surgical logistics and hospital admission coordination, and written English-language reporting of all findings and recommendations.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 comments